



West Pharmaceutical Services, Inc.

Investor Presentation

November/December 2018



Safe Harbor Statement

Cautionary Statement Under the Private Securities Litigation Reform Act of 1995

This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product development and operational performance. Each of these statements is based on preliminary information, and actual results could differ from any preliminary estimates. We caution investors that the risk factors listed under “Cautionary Statement” in our press releases, as well as those set forth under the caption “Risk Factors” in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially from those estimated or predicted in the forward-looking statements. You should evaluate any statement in light of these important factors. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.


Non-U.S. GAAP Financial Measures

Certain financial measures included in these presentation materials, or which may be referred to in management’s discussion of the Company’s results and outlook, have not been calculated in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and therefore are referred to as non-GAAP financial measures. Non-GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with GAAP. Please refer to “Reconciliation of Non-GAAP Measures” at the end of these materials for more information.


Trademarks

Registered trademarks used in this report are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless noted otherwise. Daikyo Crystal Zenith® is a registered trademark of, and is licensed from, Daikyo Seiko, Ltd.


West Business at a Glance*



- Americas
- Europe, Middle East, Africa
- Asia Pacific



- PROPRIETARY PRODUCTS
- High-Value Components
 - Standard Packaging
 - Delivery Devices
 - Contract-Manufactured Products



- PROPRIETARY PRODUCTS
- Pharma
 - Generics
 - Biologics
 - Contract-Manufactured Products



>2,000 Customers
Largest Customer: ~7% of Total Sales



>7,500 Employees



50 Locations
28 Manufacturing Sites

* Based on 2017 consolidated net sales



2018 Third-Quarter Results & Full-Year Outlook



- Q3 2018 reported net sales of \$431.7 million, representing 9.6% organic sales growth
- Q3 2018 reported-diluted EPS was \$0.73, compared to \$0.67 for the same period last year
- Excluding restructuring-related and other charges, Q3 2018 adjusted-diluted EPS⁽¹⁾ was \$0.76.
- 2018 financial guidance (as provided on October 25, 2018):
 - Full-year 2018 net sales guidance range of \$1.720 billion to \$1.730 billion
 - Full-year 2018 adjusted-diluted EPS range of \$2.80 to \$2.90

(1) Please refer to “Notes to Non-GAAP Financial Measures” on slides 12-15 and to “Non-GAAP Financial Measures” in WST’s Q3 2018 press release for additional information regarding adjusted-diluted EPS.

Organic Sales Growth

Abbreviations: LSD – low-single digit; MSD – mid-single digit; HSD – high-single digit; DD – double digit

	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018
Overall Organic Sales Growth	3.7%	4.5%	0.2%	9.0%	9.6%
Biologics	MSD	DD	(LSD)	LSD	(MSD)
Generics	LSD	HSD	HSD	DD	MSD
Pharma	(MSD)	(MSD)	(HSD)	HSD	DD
Contract Manufacturing	DD	DD	HSD	DD	DD

Self Injection Update

- SmartDose® Drug Delivery Platform
 - FDA-approved with two full years of commercial experience
 - Active clinical development programs
 - Solid pipeline of customer interest
- SelfDose® Patient Controlled Injector
 - Commercial launch in 2018
 - Award-winning technology
 - Rising customer demand
 - Additional pipeline opportunities identified

SMARTDOSE®



SELFDOSE®

Integrated Solutions Program Launched

Simplify the Journey™

- West's Integrated Solutions Program offers suites of products, combined with expert testing and support services for the unique needs of the drug product and its delivery system
- New option to make the move to market fast, while reducing risk and mitigating regulatory complexity for customers



Gross Profit Update

(\$ millions)

	Three Months Ended September 30,	
	2018	2017
Proprietary Products:		
Gross Profit	\$120.4	\$110.6
Gross Profit Margin	37.0%	35.8%
Contract-Manufactured Products:		
Gross Profit	\$15.2	\$14.5
Gross Profit Margin	14.3%	16.3%
Consolidated Gross Profit	\$135.6	\$125.1
Consolidated Gross Profit Margin	31.4%	31.4%

Cash Flow and Balance Sheet Metrics

(\$ millions)

CASH FLOW ITEMS

(UNAUDITED)
(in millions)

	Nine Months Ended September 30,	
	2018	2017
Depreciation and amortization	\$78.1	\$71.8
Operating cash flow	\$215.4	\$181.8
Capital expenditures	\$74.7	\$101.3

FINANCIAL CONDITION

(UNAUDITED)
(in millions)

	As of September 30, 2018	As of December 31, 2017
Cash and cash equivalents	\$297.3	\$235.9
Debt	\$196.2	\$197.0
Equity	\$1,351.8	\$1,279.9
Working capital	\$561.3	\$464.0


West Differentiated Solutions: Integrated Containment & Delivery

Increasing
value to West



Product Net Sales & Margin Growth

2013-2017 compound annual net sales growth rates
(excludes currency)



HVP components went from 34% of net sales in 2012 to 41% of net sales in 2017

2017 Category Gross Margin %

Circles reflect relative size of 2017 net sales

Notes to Non-GAAP Financial Measures

For additional details, please see WST's Q3 2018 press release & Safe Harbor Statement

These presentation materials use the following financial measures that have not been calculated in accordance with generally accepted accounting principles (GAAP) accepted in the U.S., and therefore are referred to as non-GAAP financial measures:

- Net sales at constant currency (organic sales)
- Adjusted operating profit
- Adjusted operating profit margin
- Adjusted net income
- Adjusted income tax expense
- Adjusted diluted EPS

West believes that these non-GAAP measures of financial results provide useful information to management and investors regarding business trends, results of operations, and the Company's overall performance and financial position. Our executive management team uses these financial measures to evaluate the performance of the Company in terms of profitability and efficiency, to compare operating results to prior periods, to evaluate changes in the operating results of each segment, and to measure and allocate financial resources to our segments. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in comparing its financial measures with other companies.

Our executive management does not consider such non-GAAP measures in isolation or as an alternative to such measures determined in accordance with GAAP. The principal limitation of these financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. In order to compensate for these limitations, non-GAAP financial measures are presented in connection with GAAP results. We urge investors and potential investors to review the reconciliations of our non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate the Company's business.

Net sales at constant currency translates the current-period reported sales of subsidiaries whose functional currency is other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. In calculating adjusted operating profit, adjusted income tax expense, adjusted net income and adjusted diluted EPS, we exclude the impact of items that are not considered representative of ongoing operations. Such items generally include restructuring and related costs, certain asset impairments, other specifically identified gains or losses, and discrete income tax items.

Please see "Financial Guidance" and "Non-GAAP Financial Measures" in WST's Q3 2018 press release for further information concerning reconciling items.

Notes to Non-GAAP Financial Measures

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

See “Notes to Non-GAAP Financial Measures” (Slides 12-15), “Cautionary Statement” (Slide 2) and WST’s Q3 2018 press release for an explanation and reconciliation of these items.

Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS (\$ million, except EPS data)

	Operating profit	Income tax expense	Net income	Diluted EPS
Three months ended September 30, 2018				
Reported (GAAP)	\$60.8	\$8.0	\$55.2	\$0.73
Restructuring and related charges	1.2	0.3	0.9	0.01
Argentina devaluation	1.1	-	1.1	0.02
Tax law changes	-	(0.4)	0.4	-
Adjusted (Non-GAAP)	\$63.1	\$7.9	\$57.6	\$0.76
Nine months ended September 30, 2018				
Reported (GAAP)	\$174.5	\$26.5	\$154.9	\$2.05
Restructuring and related charges	6.7	1.5	5.2	0.07
Argentina devaluation	1.1	-	1.1	0.02
Tax law changes	-	4.1	(4.1)	(0.06)
Adjusted (Non-GAAP)	\$182.3	\$32.1	\$157.1	\$2.08

Notes to Non-GAAP Financial Measures

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

See “Notes to Non-GAAP Financial Measures” (Slides 12-15), “Cautionary Statement” (Slide 2) and WST’s Q3 2018 press release for an explanation and reconciliation of these items.

Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS guidance

	Full Year 2018 Guidance*
Reported-diluted EPS guidance	\$2.71 to \$2.86
Restructuring and related charges	0.08 to 0.13
Argentina devaluation	0.02
Tax law changes	(0.06)
Adjusted-diluted EPS guidance	\$2.80 to \$2.90

* Guidance includes various currency exchange rate assumptions, most significantly the euro at \$1.15 for the remainder of 2018. Actual results will vary as a result of exchange rate variability.

Appendix: Reconciliation of Non-GAAP Measures

	2017	2016	2015	2014	2013
Reported-Diluted EPS (GAAP)	\$1.99	\$1.91	\$1.30	\$1.75	\$1.57
Venezuela deconsolidation	0.15	-	-	-	-
Venezuela currency devaluation	-	0.04	-	-	-
Pension settlement charge	-	-	0.43	-	-
Pension curtailment gain	-	(0.01)	-	-	-
Executive retirement and related costs	-	-	0.09	-	-
License costs	-	-	-	0.01	-
Restructuring and related charges	-	0.23	-	-	-
Tax law changes	0.64	0.01	0.01	0.02	0.06
Adjusted-Diluted EPS (Non-GAAP)	\$2.78	\$2.18	\$1.83	\$1.78	\$1.63

